SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibody
{fullname}
About author
You should write because you love the shape of stories and sentences and the creation of different words on a page.
View all posts
Related posts
---
SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats
Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness. SK
---
SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund
SK bioscience's board approval follows the Financial Services Commission's May 28 announcement selecting the
---
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP)
---
SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
No patent infringement found in exports of individual conjugate bulk substances and research-use finished
---
SK bioscience Signs Vaccine Technology Transfer Agreement with Colombia's VECOL to Advance Local Vaccine Manufacturing in Latin America
SK bioscience collaborates with Colombia's government-led US$260 million vaccine localization initiative
---
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand,
